Arbutus Biopharma Corp logo

Arbutus Biopharma Corp

ABUS
Healthcare|Biotechnology|USA
$4.79
-0.34 (-6.52%)
Tangible Book
$1.32
Graham Number
$4.93

About

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Stock Price

+46.0%(1Y)

Pipeline Summary

13 total trials
7
Phase 1
7
Phase 2
0
Phase 3
0
Phase 4
Terminated: 5Completed: 5Recruiting: 2Withdrawn: 1

Active Trials (2)

Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
NCT06154278Chronic Hepatitis B
Phase 2Recruiting
Enrollment: 10 participants
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
NCT06277037Long Term Follow-up
Recruiting
Enrollment: 50 participants

BioScore

4.3/10
Cautious

Ownership

Recent Insider Trades

HASTINGS DAVID CSELL
2025-02-0422,183 shares @ $3.28
Sims KarenSELL
2025-02-0419,348 shares @ $3.28
McElhaugh Michael J.SELL
2025-02-0423,790 shares @ $3.28
Naftzger J. ChristopherSELL
2025-02-0411,333 shares @ $3.28
MANCHESTER KEITH SSELL
2024-08-148,846 shares @ $3.69
Data last updated: Jul 13, 2026, 12:49 PM